Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)

Small Molecules Studied

HMS LINCS ID Name Alternative Names LINCS ID Structure Image PubChem CID
10107 MG-132 LSM-1107 462382
10107-2 MG-132 LSM-1107 462382
10102-3 Taxol
Paclitaxel
 LSM-1102 441276
10099-2 Nilotinib
AMN-107
 LSM-1099 644241
10098-2 Gefitinib
ZD1839; Iressa
 LSM-1098 123631
10097-3 Erlotinib
OSI-774
 LSM-1097 176870
10096-2 ZM-447439 LSM-1096 9914412
10062-3 GSK1070916
KIN001-216
 LSM-1062 46885626
10056-2 Selumetinib
AZD6244; Array142886
 LSM-1056 10127622
10052-3 Sirolimus
Rapamycin
 LSM-1052 5040
10051-3 Lapatinib
GW-572016; Tykerb
 LSM-1051 208908
10048 PD184352
CI-1040
 LSM-1048 6918454
10048-7 PD184352
CI-1040
 LSM-1048 6918454
10048-6 PD184352
CI-1040
 LSM-1048 6918454
10035-2 Sigma A6730
KIN001-102; AKT inhibitor VIII; Akt1/2 kinase inhibitor
 LSM-1035 10196499
10026-3 PD173074 LSM-1026 1401
10023-3 Imatinib
Gleevec; Glivec; CGP-57148B; STI-571
 LSM-1023 5291
10021-5 Tozasertib
VX680; MK-0457
 LSM-1021 5494449
10013-3 GSK461364
GSK461364A
 LSM-1013 15983966
10008-3 Sorafenib
BAY-439006
 LSM-1008 216239